FDA Approvals, News & UpdatesNewsworthy

Ibrutinib First Treatment Approved by the FDA for Chronic Graft-versus-Host Disease

December 2017 Vol 3 No 6

On August 2, 2017, the FDA approved a new indication for Imbruvica (ibrutinib; from Pharmacyclics) for adults with chronic graft-versus-host disease after 1 or more systemic therapies. Imbruvica is the first drug approved specifically for patients with this type of cancer. Imbruvica was previously approved by the FDA for different types of leukemia and lymphoma.

The approval was based on a clinical trial in which 88% of patients had 2 or more organs involved at the start of the study. The use of Imbruvica led to improvement in all the involved organs, and in many patients this improvement lasted 5 months or longer.

Recommended For You
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
BiomarkersFDA Approvals, News & Updates
Tabrecta Approved for NSCLC with MET Biomarker

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

FDA Approvals, News & UpdatesOvarian Cancer
Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy.

CholangiocarcinomaFDA Approvals, News & Updates
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.